Key stats
About GBLX CURE ETF UNITS
Home page
Inception date
Nov 8, 2018
Replication method
Physical
Dividend treatment
Distributes
Income tax type
Capital Gains
ISIN
AU0000028110
The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.89%
Health Technology99.89%
Bonds, Cash & Other0.11%
Cash0.11%
Stock breakdown by region
North America95.89%
Europe4.11%
Latin America0.00%
Asia0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
CURE top holdings are Alnylam Pharmaceuticals, Inc and Blueprint Medicines Corp., occupying 3.23% and 2.99% of the portfolio correspondingly.
CURE last dividends amounted to 0.02 AUD. The year before, the issuer paid 6.26 AUD in dividends, which shows a 25.93 K% decrease.
CURE assets under management is 29.55 M AUD. It's fallen 3.13% over the last month.
CURE fund flows account for −6.84 M AUD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
CURE shares are issued by Mirae Asset Global Investments Co., Ltd. under the brand Global X. The ETF was launched on Nov 8, 2018, and its management style is Passive.
CURE expense ratio is 0.45% meaning you'd have to pay 0.45% of your investment to help manage the fund.
CURE follows the S&P Biotechnology Select Industry. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
CURE invests in stocks.
CURE price has risen by 1.52% over the last month, and its yearly performance shows a −9.48% decrease. See more dynamics on CURE price chart.
NAV returns, another gauge of an ETF dynamics, have fallen by −1.76% over the last month, showed a −7.45% decrease in three-month performance and has decreased by −7.62% in a year.
NAV returns, another gauge of an ETF dynamics, have fallen by −1.76% over the last month, showed a −7.45% decrease in three-month performance and has decreased by −7.62% in a year.
CURE trades at a premium (0.38%) meaning the ETF is trading at a higher price than the calculated NAV.